Hyperlipidemia associated with protease inhibitor therapy

Annals of Pharmacotherapy

Volumn 33, Issue 7-8, 1999, Pages 859-863

  Echevarria, Kelly L ^a,b,e   Hardin, Thomas C ^c   Smith, Jean A ^d  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b PARKLAND HEALTH AND HOSPITAL SYSTEM   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d Mays Cancer Center at UT Health San Antonio   (United States)

^e NONE   (United States)

Author keywords

Human immunodeficiency virus; Hyperlipidemia; Protease inhibitors

Indexed keywords

ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; CHOLESTEROL; DIDANOSINE; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; CASE REPORT; CHOLESTEROL BLOOD LEVEL; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; HYPOCHOLESTEROLEMIA; MALE; PANCREATITIS; PATIENT CARE; PRIORITY JOURNAL; TREATMENT PLANNING;

EID: 0032769255     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.18174     Document Type: Article

References (24)

1. Kakuda T, Struble K, Piscitelli S. Protease inhibitors for the treatment of human immunodeficiency virus infection. Am J Health Syst Pharm 1998; 55:233-54.
2. Tal A, Dall L. Didanosine-induced hypertriglyceridemia (letter). Am J Med 1993;95:247.
3. Grunfeld C, Pang M, Doerrler W, Shigenaga J, Jensen P, Feingold K. Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome. J Clin Endocrinol Metab 1992;74:1045-52.
4. Constans J, Pellegrin JL, Peuchant E, Dumon M, Pellegrin I, Sergeant C, et al. Plasma lipids in HIV-infected patients: a prospective study in 95 patients. Eur J Clin Invest 1994;24:416-20.
5. Shor-Posner G, Basit A, Lu Y, Cabrejos C, Chang J, Fletcher M, et al. Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency virus-1 infection. Am J Med 1993;94:515-9.
6. Grunfeld C, Kotler D, Shigenaga J, Doerrler W, Tierney A, Wang J, et al. Circulating interferon-α levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1991;90:154-61.
7. Mildvan D, Machado S, Wilets I, Grossberg S. Endogenous interferon and triglyceride concentrations to assess response to zidovudine in AIDS and AIDS-related complex. Lancet 1992;339:453-6.
8. Hellerstein M, Grunfeld C, Wu K, Christiansen M, Kaempfer S, Kletke C, et al. Increased de novo hepatic lipogenesis in human immunodeficiency virus infection. J Clin Endocrinol Metab 1993;76:559-65.
9. Guidelines for use of antiretroviral agents in HIV infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998;47(RR-05).
10. Ginsburg C, Salmon-Ceron D, Vassilief D, Rabian C, Rotschild C, Fontenay-Roupie M, et al. Unusual occurrence of spontaneous hematomas in three asymptomatic HIV-infected haemophilia patients a few days after the onset of ritonavir treatment. AIDS 1997;11:388-9.
11. Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated with protease inhibitors (letter). Lancet 1997;350:1596.
12. Product information, M94-245. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, May 1996.
13. Product information, M94-247. Norvir (ritonavir). North Chicago, IL: Abbott Laboratories, May 1996.
14. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995;333:1528-33.
15. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
16. Sullivan AK, Nelson MR. Marked hyperlipidemia on ritonavir therapy. AIDS 1997;11:938-9.
17. Product information. Crixivan (indinavir). West Point, PA: Merck & Co., March 1996.
18. Roberts AD, Muesing RA, Parenti DM, Hsia J, Wasserman AG, Simon GL. Alterations in serum lipids and lipoproteins with indinavir in HIV-infected patients (abstract). Clin Infect Dis 1997;25:398.
19. Product information. Viracept (nelfinavir). La Jolla, CA: Agouron Pharmaceuticals, March 1997.
20. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm D, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998;12:F51-8.
21. Tabib A, Greenland T, Mercier I, Loire R, Moirnex J. Coronary lesions in young HIV-positive subjects at necroscopy (letter). Lancet 1992;340: 730.
22. Paton P, Tabib A, Loire R, Tete R. Coronary artery lesions and human immunodeficiency virus infection. Res Virol 1993;144:225-31.
23. Henry K, Melroe H, Huebsch J, Hermundson J, Levine C, Swensen L, et al. Severe premature coronary artery disease with protease inhibitors (letter). Lancet 1998;351:1328.
24. Roche, FDA announce new drug-interaction warnings for mibefradil. Am J Health Syst Pharm 1998;55:210.